SEC Comment Letter 0000000000-25-003798 to REVELATION BIOSCIENCES, INC. (REVB)

REVELATION BIOSCIENCES, INC.
Date: April 9, 2025 · CIK: 0001810560 · Accession: 0000000000-25-003798

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 9, 2025

Author

Division of

Form

UPLOAD

Company

REVELATION BIOSCIENCES, INC.

Letter

Re: Revelation Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted April 4, 2025 CIK No. 0001810560 Dear James Rolke:

April 9, 2025

James Rolke Chief Executive Officer Revelation Biosciences, Inc. 4660 La Jolla Village Drive, Suite 100 San Diego, CA 92122

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: J.P. Galda, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 9, 2025

James Rolke
Chief Executive Officer
Revelation Biosciences, Inc.
4660 La Jolla Village Drive, Suite 100
San Diego, CA 92122

 Re: Revelation Biosciences, Inc.
 Draft Registration Statement on Form S-1
 Submitted April 4, 2025
 CIK No. 0001810560
Dear James Rolke:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: J.P. Galda, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io